<SEC-DOCUMENT>0001193125-24-072810.txt : 20240320
<SEC-HEADER>0001193125-24-072810.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320170414
ACCESSION NUMBER:		0001193125-24-072810
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-277634
		FILM NUMBER:		24768485

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d806167d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR> Registration No. 333-277634 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g806167g34v27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>106,480,057 shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 106,480,057
shares of our common stock, which consists of (i) 105,730,057 shares of our common stock held by the selling stockholders and (ii) 750,000 shares of our common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock held by one of the selling stockholders, all of which were issued by us in two concurrent private placements on February&nbsp;7, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling
stockholders of such shares. We will, however, receive the exercise price of $0.0001 per share of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercised for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of the shares by the selling stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related
to prevailing market prices or at negotiated prices. The selling stockholders may sell shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling
stockholders, the purchasers of the shares, or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are paying the cost of registering the shares of common stock covered by this
prospectus as well as various related expenses. The selling stockholders are responsible for all broker or similar commissions related to the offer and sale of their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &#147;ADVM.&#148; On March&nbsp;19, 2024, the last
reported sale price of our common stock was $1.65 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our common stock involves a high degree of risk. Before making an investment decision, you should review carefully the risks described under the heading &#147;<A HREF="#tx806167_4">Risk Factors</A>&#148; on page 4 of this prospectus and under
similar headings in any amendment or supplement to this prospectus or in any filing with the Securities and Exchange Commission that is incorporated by reference herein. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is March&nbsp;20, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_10">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx806167_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission, or SEC, using a &#147;shelf&#148; registration process. Under this registration statement, the selling stockholders may sell from time to time in one or more offerings the common stock described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholders have authorized anyone to provide you with information other than the information that we have
provided or incorporated by reference in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. If anyone provides you with different or inconsistent
information, you should not rely on it. . This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted.&nbsp;You should assume that the
information appearing in this prospectus or any prospectus supplement, is accurate only as of the date of this prospectus or such prospectus supplement and that any information we have incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of our common stock. Our business, financial condition and results of operations may have changed since
those dates. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any applicable prospectus supplement or free writing prospectus, including the documents that we incorporate by reference
herein and therein, contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or
the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be
materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future
events and are based on assumptions and are subject to risks and uncertainties. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We discuss many of these risks in greater detail under &#147;Risk Factors&#148; in this
prospectus, in the &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections incorporated by reference from our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, these
forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to
reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus,
any applicable prospectus supplement, together with the documents that we have filed with the SEC that are incorporated by reference and any free writing prospectus we have authorized for use in connection with this offering, completely and with the
understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, the Private Placements (as defined below) and selected information contained
elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of our company,
you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement, including the factors described under the heading &#147;Risk Factors&#148; on
page&nbsp;4 of this prospectus, as well as the information incorporated herein by reference, before making an investment decision. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context indicates otherwise, references in this prospectus to &#147;Adverum,&#148; &#147;Adverum Biotechnologies,&#148;
&#147;the Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Adverum Biotechnologies, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company
Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular
diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, ixoberogene soroparvovec <FONT STYLE="white-space:nowrap">(&#147;Ixo-vec&#148;),</FONT> formerly referred to as <FONT
STYLE="white-space:nowrap">ADVM-022,</FONT> is a single, <FONT STYLE="white-space:nowrap">in-office</FONT> intravitreal (&#147;IVT&#148;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept
associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor IVT injections. <FONT STYLE="white-space:nowrap">Ixo-vec</FONT> is
currently being developed for the treatment of patients with wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, also known as neovascular AMD, and is being evaluated in the ongoing LUNA Phase 2 trial. We are also
developing an early-stage pipeline of gene therapy programs targeting the treatment of other highly prevalent ocular diseases. Our core capabilities include novel vector evaluation, cassette engineering, ocular
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> nonclinical and clinical development, scalable process development, assay development, and current Good Manufacturing Practices quality control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in Delaware in 2006 under the name &#147;Avalanche Biotechnologies, Inc.&#148; We completed the initial public offering of our common stock in August 2014. On May&nbsp;11, 2016, upon the completion of our acquisition of Annapurna Therapeutics SAS,
we changed our name to &#147;Adverum Biotechnologies, Inc.&#148; Our common stock is currently listed on The Nasdaq Capital Market under the symbol &#147;ADVM.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">656-9323.</FONT> Our website address is www.adverum.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual
reference only. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2024, we entered into a securities purchase agreement, or the Securities Purchase Agreement, with certain of the selling
stockholders named in this prospectus, pursuant to which we issued and sold the following securities to such selling stockholders in a private placement transaction, which we refer to as the Private Placement: (i) 105,500,057 shares of our common
stock and (ii)&nbsp;with respect to one of the selling stockholders, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase an aggregate of 750,000 shares of common stock in lieu of shares
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of common stock. The purchase price per share of common stock was $1.20, and the purchase price per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant was $1.1999. Each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant has an exercise price equal to $0.0001 per share. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance on February&nbsp;7, 2024
and will not expire until exercised in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not effect the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants and the selling stockholder that holds <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be entitled to request the exercise of any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if such
holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise, or the Beneficial Ownership Limitation. The holder may reset
the Beneficial Ownership Limitation as to itself to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing investors that previously held five percent or more of our outstanding common stock, including Commodore Capital Master LP, FMR LLC
and Venrock Healthcare Capital Partners III, L.P., and/or their affiliates, are party to the Securities Purchase Agreement, and purchased approximately $7.0&nbsp;million, $10.0&nbsp;million and $12.5&nbsp;million, respectively, in shares of common
stock in the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the Private Placement, we also entered into a securities purchase agreement, or the
Director Securities Purchase Agreement, and, together with the Securities Purchase Agreement, the Securities Purchase Agreements, with Mark Lupher, Ph.D., and James Scopa, directors of the Company, pursuant to which we agreed to issue and sell to
such selling stockholders in a private placement, which, together with the Private Placement, we refer to as the Private Placements, 230,000 shares of common stock at a purchase price per share of common stock of $1.35, on otherwise substantially
the same terms as those set forth in the Securities Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our total gross proceeds from the sale of securities in the
Private Placements, before deducting placement agent fees and offering expenses, was approximately $127.8&nbsp;million, which does not include any proceeds that may be received upon exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants issued in the Private Placements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placements, we entered into a registration rights agreement, or
the Registration Rights Agreement, with the selling stockholders named in this prospectus pursuant to which we agreed to prepare and file, within 45 days after the closing of the Private Placements, a registration statement with the SEC to register
the resale of (i)&nbsp;shares of our common stock issued in the Private Placements and (ii)&nbsp;shares of our common stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in the Private Placements, and
to use reasonable best efforts to cause such registration statement to become effective within 75 days after the closing of the Private Placements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding the Private Placements, see our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000119312524024156/d739306d8k.htm">Form
 <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed with the SEC on February&nbsp;5, 2024 and incorporated herein by reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by the selling stockholders </P></TD>
<TD>106,480,057 shares, consisting of (i) 105,730,057 shares of our common stock held by the selling stockholders and (ii) 750,000 shares of our common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock held by one of the selling stockholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the offering </P></TD>
<TD>Each selling stockholder will determine when and how it will sell the common stock offered in this prospectus, as described in &#147;Plan of Distribution.&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. We will, however, receive de minimis proceeds upon exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for cash.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; on page&nbsp;4 for a discussion of factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq symbol </P></TD>
<TD>&#147;ADVM&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to 106,480,057 shares of our
common stock. Our common stock is currently listed on Nasdaq under the symbol &#147;ADVM.&#148; Shares of our common stock that may be offered under this prospectus will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> We
will not receive any of the proceeds of sales by the selling stockholders of any of the common stock covered by this prospectus. We will, however, receive the exercise price of $0.0001 per share of any of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercised for cash. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer and resale, we are referring
to the shares of common stock that have been issued to the selling stockholders and the shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in the Private Placements as described
above. When we refer to the selling stockholders in this prospectus, we are referring to the selling stockholders identified in this prospectus and, as applicable, their permitted transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus is a part. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks
described in the sections entitled &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as filed with
the SEC, which are incorporated herein by reference in their entirety, as well any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any applicable prospectus supplement. Our business, financial
condition, results of operations or prospects could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus
and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of
certain factors, including the risks mentioned elsewhere in this prospectus. For more information, see the below section &#147;Where You Can Find Additional Information.&#148; Please also read carefully the above section &#147;Special Note Regarding
Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale or other disposition of shares of our common stock held by the selling stockholders
pursuant to this prospectus. Upon any exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for cash, the selling stockholder that holds <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants would pay us the exercise
price set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant has an exercise price equal to $0.0001 per share, and if all 750,000 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised on a cash basis, we will receive de minimis
proceeds of $75. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance on February&nbsp;7, 2024 and will not expire until exercised in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable on a net exercise cashless basis. If any of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised on a cashless basis, we would not receive any cash payment from the applicable selling stockholder upon any such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, expenses and fees
incurred in connection with the registration of shares of our common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration expenses, the selling stockholders will bear their own broker or similar
commissions payable with respect to sales of shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock being offered by the selling stockholders are those (i)&nbsp;issued to the selling stockholders in the Private
Placements and (ii)&nbsp;issuable to the selling stockholder that holds <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in the Private Placements.
For additional information regarding the issuance of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, see the section &#147;Prospectus Summary&#151;Private Placements&#148; above. We are registering the
resale of shares of common stock issued to the selling stockholders and issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in order to permit the selling stockholders to offer the shares for resale from time to
time. Except for the ownership of the shares of common stock and the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and for the selling stockholders whose other relationships are provided in &#147;Relationships with Selling
Stockholders,&#148; the selling stockholders have not had any material relationship with us within the past three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common stock. Generally, a person &#147;beneficially owns&#148; shares of our common stock if the person has or shares with
others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights within 60 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each
of the selling stockholders. This information has been obtained from the selling stockholders or in Schedules 13G or 13D and other public documents filed with the SEC. The second column lists the number of shares of common stock beneficially owned
by each selling stockholder, based on its ownership of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, as of February&nbsp;7, 2024, assuming exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants held by the selling stockholder that holds <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on that date, subject to the beneficial ownership limitation described below. The percentage of shares owned prior to and after the
offering in the third and sixth columns are based on 207,163,393 shares of common stock outstanding as of February&nbsp;7, 2024. The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration Rights Agreement, this prospectus generally covers the resale of the sum of (i)&nbsp;the
number of shares of common stock issued to the selling stockholders in the Private Placements and (ii)&nbsp;the maximum number of shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued
in the Private Placements. This maximum amount is determined as if the outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were exercised in full as of the trading day immediately preceding the date this registration statement
was initially filed with the SEC, subject to adjustment as provided in the Registration Rights Agreement and without regard to any limitations on the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Under the terms of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the selling stockholder that holds <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may not exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to the
extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 9.99% of the number of shares of our common stock outstanding
following such exercise (for purposes of the denominator, immediately after giving effect to the issuance of shares of common stock to be issued upon the applicable exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants). The
number of shares in the second column reflect this limitation. The selling stockholders may sell all, some or none of their shares in this offering. See the section &#147;Plan of Distribution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Address</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number<BR>of Shares<BR>Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover Fund II, L.P. <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> <BR>705 High
Street<BR>Palo Alto, CA 94301</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,763,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,833,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5AM Opportunities II, L.P.<SUP STYLE="font-size:75%; vertical-align:top"> (2)</SUP><SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;</SUP><BR>c/o 5AM Ventures<BR>501 2nd Street, Suite<BR>350 San Francisco, CA 94107</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,916,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,916,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Life Sciences Fund LLC <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP> <BR>110
Greene Street, Suite 800<BR>New York, NY 10012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital Master LP <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP> <BR>444
Madison Avenue, 35th Floor<BR>New York, NY 10022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,139,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,306,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Select Portfolios: Biotechnology Portfolio <SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP> <BR>245 Summer Street<BR>Boston, MA 02210</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,398,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,064,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Franklin Advisers
<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;<BR>c/o Franklin Advisers, Inc.<BR>One Franklin Parkway<BR>San Mateo, CA 94403</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,173,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,756,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Life Sciences
<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP><BR>1001 Page Mill Rd., Building 4, Ste. B<BR>Palo Alto, CA 94304</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Logos Global
<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP><BR>1 Letterman Drive, Building C, Suite <FONT STYLE="white-space:nowrap">C3-350</FONT><BR>San Francisco, CA 94129</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, LP <SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP> <BR>628
Middlefield Road<BR>Palo Alto, CA 94031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,916,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,916,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock Healthcare Capital Partners <SUP
STYLE="font-size:75%; vertical-align:top">(10)</SUP><BR>7 Bryant Park, 23rd Floor<BR>New York, New York 10018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,564,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,416,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,147,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivo Opportunity Fund Holdings, L.P.
<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP><BR>c/o Vivo Capital LLC<BR>192 Lytton Avenue<BR>Palo Alto, CA 94301</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark L. Lupher, Jr. <SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP><BR>c/o Adverum
Biotechnologies, Inc.<BR>100 Cardinal Way<BR>Redwood City, California 94063</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Scopa <SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP><BR>c/o Adverum
Biotechnologies, Inc.<BR>100 Cardinal Way<BR>Redwood City, California 94063</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 20,083,395 shares of common stock purchased in the Private Placements by TCG Crossover Fund II,
L.P. and (b) 680,177 shares of common stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased in the Private Placements by TCG Crossover Fund II, L.P. This total excludes 69,823 shares of common stock
issuable upon exercise of certain <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants because the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may not be exercised to the extent that doing so would result in the holder of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants (together with the holder&#146;s affiliates and any other persons acting as a group together with the holder or any of the holder&#146;s affiliates) beneficially owning more than 9.99% of the
shares of common stock then outstanding immediately after giving effect to such exercise. TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II, L.P. and may be deemed to have voting, investment, and dispositive power with respect
to these securities. Chen Yu is the sole managing member of TCG Crossover GP II, LLC and may be deemed to share voting, investment and dispositive power with respect to these securities. The principal business address of these persons and entities
is 705 High Street, Palo Alto, CA 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,916,666 shares of common stock purchased in the Private Placements by 5AM Opportunities II, L.P.,
or 5AM Opportunities. 5AM Opportunities II (GP), LLC is the general partner of 5AM Opportunities and may be deemed to have sole investment and voting power over the shares held by 5AM Opportunities. Andrew Schwab and Kush Parmar are the managing
members of 5AM Opportunities II (GP), LLC, and may be deemed to share voting and dispositive power over the shares held by 5AM Opportunities. The address of 5AM Opportunities is c/o 5AM Ventures, 501 2nd Street, Suite 350, San Francisco, CA 94107.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,166,666 shares of common stock purchased in the Private Placements by Avoro Life Sciences Fund
LLC. Avoro Capital Advisors LLC (&#147;Avoro&#148;) is the investment advisor for Avoro Life Sciences Fund LLC. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro and may be deemed to have investment discretion and
voting power over the shares held by Avoro. Mr.&nbsp;Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of Avoro Life Sciences Fund LLC is 110 Greene Street,
Suite 800, New York, NY 10012. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 12,139,625 shares of common stock held by Commodore Capital Master LP, of which (a) 6,306,292 are
shares of common stock held by Commodore Capital Master LP prior to the Private Placements and (b) 5,833,333 are shares of common stock purchased in the Private Placements by Commodore Capital Master LP. Commodore Capital LP is the investment
manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment
discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison
Avenue, 35th Floor, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a
Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of
the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form
a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 5,820,371 shares of common stock held by Franklin Strategic Series &#150; Franklin
Biotechnology Discovery Fund (&#147;FSS&#148;), of which (i) 2,301,100 are shares of common stock held by FSS separately from the Private Placements and (ii) 3,519,271 are shares of common stock purchased in the Private Placements by FSS; (b)
11,352,495 shares of common stock held by Franklin Templeton Investment Funds &#150; Franklin Biotechnology Discovery Fund (&#147;FTIF&#148;), of which (i) 4,455,100 are shares of common stock held by FTIF separately from the Private Placements and
(ii) 6,897,395 are shares of common stock </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
purchased in the Private Placements by FTIF; and (c) 472 shares of common stock held by Franklin Biotechnology Discovery SMA (&#147;SMA&#148;). Evan McCulloch has voting and/or dispositive power
over the holdings of FSS, FTIF and SMA. Mr.&nbsp;McCulloch disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Franklin Advisers, Inc. is the investment adviser for each of FSS, FTIF and SMA.
The principal business address of these persons and entities is One Franklin Parkway, San Mateo, CA 94403. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 5,003,125 shares of common stock purchased in the Private Placements by Frazier Life Sciences
Public Fund, L.P. (&#147;FLS Public Fund&#148;), (b) 2,395,833 shares of common stock purchased in the Private Placements by Frazier Life Sciences Public Overage Fund, L.P. (&#147;FLS Overage Fund&#148;), (c) 2,000,000 shares of common stock
purchased in the Private Placements by Frazier Life Sciences XI, L.P. (&#147;FLS XI&#148;) and (d) 1,017,708 shares of common stock purchased in the Private Placements by Frazier Life Sciences X, L.P. (&#147;FLS X&#148;). FHMLSP, L.P. is the general
partner of FLS Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N. Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and therefore share voting and investment power over the
shares held by FLS Public Fund. Dr.&nbsp;Cha, Dr.&nbsp;Topper, Mr.&nbsp;Heron and Dr.&nbsp;Brush disclaim beneficial ownership of the shares held by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any. FHMLSP
Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Dr.&nbsp;Cha, Dr.&nbsp;Topper, Mr.&nbsp;Heron and Dr.&nbsp;Brush are the members of FHMLSP Overage, L.L.C. and
therefore share voting and investment power over the shares held by FLS Overage Fund. Dr.&nbsp;Cha, Dr.&nbsp;Topper, Mr.&nbsp;Heron and Dr.&nbsp;Brush disclaim beneficial ownership of the shares held by FLS Overage Fund except to the extent of their
pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr.&nbsp;Heron and Dr.&nbsp;Topper are the members of FHMLS X, L.L.C. and therefore share voting
and investment power over the shares held by FLS X. Dr.&nbsp;Topper and Mr.&nbsp;Heron disclaim beneficial ownership of the shares held by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS XI, L.P. is the general
partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Mr.&nbsp;Heron, Dr.&nbsp;Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by FLS XI.
Dr.&nbsp;Topper, Mr.&nbsp;Heron and Mr.&nbsp;Estes disclaim beneficial ownership of the shares held by FLS XI except to the extent of their pecuniary interests in such shares, if any. The principal business address of the above referenced entities
and persons is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 4,166,666 shares of common stock purchased in the Private Placements by Logos Opportunities
Fund IV LP (&#147;Logos Opportunities&#148;) and (b) 10,833,334 shares of common stock purchased in the Private Placements by Logos Global Master Fund LP (&#147;Global Fund&#148;). Logos Opportunities IV GP LLC (&#147;Logos Opportunities GP&#148;)
is the general partner of Logos Opportunities. Logos Global Management LP (&#147;Logos Global&#148;) is the investment advisor to Global Fund. Logos Global Management GP LLC (&#147;Logos Global GP&#148;) is the general partner of Logos Global.
Arsani William and Graham Walmsley are the members of Logos Opportunities GP and Mr.&nbsp;William is a control person of Logos Global and Logos Global GP. Mr.&nbsp;William and Mr.&nbsp;Walmsley each disclaim beneficial ownership of these shares,
except to the extent of each&#146;s pecuniary interest in such shares, if any. The principal address of Logos Opportunities and Global Fund is 1 Letterman Drive, Building C, Suite <FONT STYLE="white-space:nowrap">C3-350,</FONT> San Francisco, CA
94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,916,666 shares of common stock purchased in the Private Placements by Samsara BioCapital, LP.
(&#147;Samsara LP&#148;). Samsara BioCapital GP, LLC (&#147;Samsara LLC&#148;) is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr.&nbsp;Srinivas Akkaraju, MD, Ph.D. has voting and investment
power over the shares held by Samsara GP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein.
The address for Samsara LP is 628 Middlefield Road, Palo Alto, CA 94031. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 11,063,043 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.
(&#147;VHCP EG&#148;), of which (i) 3,658,876 are shares of common stock held by VHCP EG prior to the Private Placements and (ii) 7,404,167 are shares of common stock purchased in the Private Placements by VHCP EG, (b) 4,091,832 shares of common
stock held by Venrock Healthcare Capital Partners III, L.P. (&#147;VHCP </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
III&#148;), of which (i) 1,353,291 are shares of common stock held by VHCP III prior to the Private Placements and (ii) 2,738,541 are shares of common stock purchased in the Private Placements by
VHCP III, and (c) 409,338 shares of common stock held by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC (&#147;VHCP Co III&#148;), of which (i) 135,380 are shares of common stock held by VHCP Co III prior to the Private
Placements and (ii) 273,958 are shares of common stock purchased in the Private Placements by VHCP Co III. VHCP Management EG, LLC (&#147;VHCPM EG&#148;) is the sole general partner of VHCP EG. VHCP Management III, LLC (&#147;VHCPM&#148;) is the
sole general partner of VHCP III and the sole manager of VHCP Co III. Dr.&nbsp;Bong Koh and Nimish Shah are the voting members of VHCPM EG and VHCPM. The address of the above referenced entities and persons is 7 Bryant Park, 23rd Floor, New York,
New York 10018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 15,000,000 shares of common stock purchased in the Private Placements by Vivo Opportunity Fund
Holdings, L.P., or Vivo Fund Holdings. Vivo Opportunity, LLC, or Vivo Opportunity, is the general partner of Vivo Fund Holdings. The voting members of Vivo Opportunity are Kevin Dai, Frank Kung, and Michael Chang, none of whom has individual voting
or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares. The address of the above referenced entities and persons is c/o Vivo Capital LLC, 192 Lytton Avenue, Palo Alto, CA 94301.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 130,000 shares of common stock purchased in the Private Placements by a traditional IRA for the
benefit of Dr. Lupher and (b) 225,000 shares of common stock subject to options that are exercisable within 60 days of February&nbsp;7, 2024 held by Dr. Lupher. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 100,000 shares of common stock purchased in the Private Placements by Mr. Scopa and (b) 225,000
shares of common stock subject to options that are exercisable within 60 days of February&nbsp;7, 2024 held by Mr. Scopa. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in greater detail above under the section &#147;Prospectus Summary&#151;Private Placements,&#148; on February&nbsp;5, 2024, we
entered into the Securities Purchase Agreements and the Registration Rights Agreement with the selling stockholders pursuant to which, on February&nbsp;7, 2024, we sold shares of our common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of common stock to the selling stockholders and agreed to file a registration statement to enable the resale of the shares of common stock covered by this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing investors that previously held five percent or more of our outstanding common stock, including Commodore Capital Master LP, FMR
LLC and Venrock Healthcare Capital Partners III, L.P., and/or their affiliates, purchased approximately $7&nbsp;million, $10&nbsp;million and $12.5&nbsp;million, respectively, in shares of common stock in the Private Placement. Concurrently with the
Private Placement, Mark Lupher, Ph.D., and James Scopa, directors of the Company, also purchased approximately $175,500 and $135,000, respectively, in shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described above, none of the selling stockholders or any persons having control over such selling stockholders has held any
position or office with us or our affiliates within the last three years or has had a material relationship with us or any of our predecessors or affiliates within the past three years, other than as a result of the ownership of our shares or other
securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder of the securities and any of their pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell, transfer or otherwise dispose of any or all of their respective securities covered hereby on Nasdaq or any other stock exchange, market or trading facility
on which the securities are traded or in private transactions. These sales may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices. A selling stockholder may use any one or more of the following methods when selling securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution to employees, members, partners or stockholders of a selling stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the distribution of such securities by any selling stockholder to its equity holders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short trades entered into after the date of this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A selling stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by a selling stockholder may arrange for other brokers-dealers to participate
in sales. Broker-dealers may receive commissions or discounts from a selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a
supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule
2121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A selling stockholder may enter into option or other transactions with broker-dealers or other financial institutions or create one
or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A selling stockholder and any broker-dealers or agents that are
involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the
resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or
indirectly, with any person to distribute the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay certain fees and expenses incurred by us incident to the
registration of the securities. We have agreed to indemnify any selling stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i)&nbsp;the date on which
the securities may be resold by the selling stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144,
without the requirement for us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii)&nbsp;all of the securities have been sold pursuant to this prospectus or Rule
144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the
resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by a selling stockholder or any other person. We will make copies of
this prospectus available to a selling stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the common stock offered hereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_10"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must comply with the informational requirements of the Exchange Act, and we are required to file reports and proxy statements and other
information with the SEC. You may read and copy these reports, proxy statements and other information on the SEC&#146;s website at http://www.sec.gov, which contains reports, proxy and information statements and other information regarding issuers
like us that file electronically with the SEC. We maintain a website at www.harpoontx.com. The information contained in, or that can be accessed through, our website is not incorporated by reference herein and is not part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each
instance, we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx806167_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC
(File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36579):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501756/000162828024011648/advm-20231231.htm">Form
 10-K</A> for the year ended December 31, 2023, filed with the SEC on March&nbsp;18, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000119312524024156/d739306d8k.htm">February
 5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000119312524025340/d17634d8k.htm">February 6, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501756/000119312524027649/d763887d8k.htm">February&nbsp;8,
 2024</A> (only as to Item 8.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501756/000119312524072709/d814195d8k.htm">March&nbsp;20, 2024</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000119312514282544/d765259d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on July&nbsp;28, 2014, under Section&nbsp;
12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Exhibit 4.2</A> of our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other
information that we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as
proxy statements. Information in such future filings updates and supplements the information provided in this prospectus. Any statement in any such future filings will automatically be deemed to modify and supersede any information in any document
we previously filed with the SEC that is incorporated by reference to the extent that statements in the later-filed document modify or replace such earlier statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral
request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct
any requests for documents to Adverum Biotechnologies, Inc., 100 Cardinal Way, Redwood City, California 94063; telephone: (650) <FONT STYLE="white-space:nowrap">656-9323.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g806167g34v27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g806167g34v27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[17J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %<Z^58(X0DE-! 0      !<< @   @  ' )0  M!<'5R=F$@1V]R90 X
M0DE-!"4      !"8F'Q%8#P2M$*^@R5Q+71%.$))300Z      $>    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
M  !21T)#     $YM("!415A4    " !# $D 10 @ %( 1P!"        26YT
M965N=6T     26YT90    !!0VQR    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92SA"24T$.P     "+0   !     !       2<')I;G1/=71P
M=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G
M<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"
M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M/X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      T$    &              !'
M   !0@    8 1 !3 %  ,  P #,    !                          $
M             4(   !'                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   !'     %)G:'1L;VYG   !0@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M1P    !29VAT;&]N9P   4(    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M;&4UOML=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M014C418R)&%QD1<8,T*!)28T-4-2<K'!_\0 ' $   <! 0
M 0(#! 4&!P (_\0 01$  @(! P(% P($! ,&!@,  0(#$2$$$C$ !083(D%1
M!V%Q%#(5(X&10E*AL3/!\!8D-$-BT24U-F-RX5.2\?_:  P# 0 "$0,1 #\
M[Z)VD"]J.P=K/ (9@1&>1P..>1R.  " ?/\ R]'2K-@&@31X]O[?G_?@DFND
MVV#:@[>?>[J_ZV/_ 'ZO,C&-T[BKK78ENX@AEX#,&YYY'/)/ //^/UZ+5G&
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M!N-$[<@,R\4" ;( ^+KWZV*=6T<!DEW':EDM=EA'OKU;:)%XNQ1!XL\\FO\
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M;K#D<CT\L)67'08;)5<G.S:O)*UB,VQ_3*]V6E99P9$P#_*)#FU5I>;MTA#
M(,;I %C"OZ4;:NX1718+C"L;K)KK"/!7U)GU/BS4=I[MKFU$#ZB985FEA1$>
M'5Q@1)4R^AX=P(*N00JE2'D!/;2='JUV2;YE,$++(TAD=U:-"&=BQ+LW()9O
MR;GDGEB3#,K*S!A1!(/Q8-$?'M[=>@?-28F5-H63^8H4  *_J "KA0 10& *
M QUE^B]#UKUR42QS?'<L0O#:D3\9Q&.^,.2A*MR8^2/P)!X '[ 'H\$J[BI5
M6LE+902.!:YP1\GD^W)Z1E1IT=XV=/(!W[&*@^4I+%BH/((NZR!N(Z!=[ROJ
M)=4^G_N2U[I#TES5:MJ6I7\/5ZG6'HK>R.6R4^:07L9A\CWR20RT:%A(KT2R
M)\;(RO"@0*+#%VU7CC=54RR*DNTH"H5J"B@A%D@,?D$V2+O"/%'U2CTO=Y?#
MW;]5MU6GG&G,L<B.SSQ2202([+K!, FH*1.GZ?<9$*DFQ&3N8"2:;!866Q(\
MMB7$8V2>60LTDDSTX6EDD9B69W<LS%B6+$DDGGU 3@+/,HH!99  H 6@[#
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MJ*%O;#U[4 2";H_U-DD[PKF2-]$SJLDA />K#_<I!!!\D\CTQ[2^^96-4P!
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M8AJRWY<E2AV(9S.3WLMCL[3NL\DVL-6PN2M6J<0!>ZV*-85D\E&DD16+[%!
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M"/'Q6HJM*88&Q-\*1B;M:>UAWL2/,WX32R-+--.#+-))(TC&=3O4<>V+<'#
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M+-CX%CK(O#OTBC[3XBU/?3,TJ'5ZK5P0^1MVB>57V.6T^U5C4D#RBHDW;B%
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M6CA,<X*QPNSJ.;;$M2$.C4$%@?M)LD'!)2L6+HX!*FC^)?"$???$?9IGE/\
MW2>)S%Y2R%Q)K2^&:%@K5$R+N5O2RGE=KD#QZ1Q4*4</R?%'4K)%\Q4S?&D*
M*GRE25,G:!\A4E>[G@D>F3L7=F-6S,QJZMB2:NS6<62?GJ_"$:<#3@[A !"&
MN[$7H!NEN]MWM%_ XZ5:M6=E=Z\#ND@F5VBC9EF4!1*K%25D"@ ."&   /'H
MMGY^W]/CI022 $!W *E" S %"22I -%2225XLG'5"O7!#""$,..&$2 CCR."
M%Y'!\CC]>N.<'(^#G[?[8Z3VK>[:-Q-DT+)N[OF[S?STMX_7C@>./_\ ./\
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M]T<1*\@$HA*@'\..5X';R>W_ !R?_DD8(W#A26 &0-M@ 5Q5 U6*Z4$CCAV
M]P&878%W1]Z%_./MU8*].(LPAKAW4HS=D7>RGD]K,%!*GCDC]>/YX]'>4JNT
MN=OLI8@8! Q8 H"L<#I/:N\R!%$A))<* Q-[B=W[N1?/.>KEBAX4_''V@,$
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MA\!2^;[1IGK8;'U<=7EL-2IX^F]AXJJ/-)6H4X6D+-%6@0K$MCTT;1(JD50
MY!LTN25 !)K)H61TN * H8 Q6+'OP,_>A\\]-7O.F=1+74/7MVTVEJ-T8O5]
MNU:]6VG,9"FL]39-CTO,*81C\#D7^-8M8D$D<DO 9H8PK#EO45)H=0=1)*B*
M0[N0Q9+*M(7S>:X]/-*!@]%._=8.* J[P&)HX6@=W LC:<G +BZFF\-C"^XT
M\/2S(E>+LP&5OY#'FLK<1R(<A#69I>T?^H]>)Y!P\D<;ED5_%%.!3%AQ_P"8
M3[ -@-1H77 )&?:^&[-C/%[F/VNBQ4GWR :P23GK2>H_3;/;!>U_;M/OT\7O
M&HKE8<7/EE%G$YK$;"^-?/Z_FVBC-Z*GDSB,7)*U5F1;6,H3&.7[2I]NSU6@
MU$GKB=A(#?\ Q*#7NO?8%D6!\$4+H8 H#D*-R\6 VX']V3=%A8-@ CTV%  U
MK&]/^I>R[/KNP=0)<1B<-J5V;)8S4-:R=K+_ -4S4T;009G,YG*)3E=,='-+
M]I3ABXACYCC[P0I1TW;]6'#3NP52"%\[=9]/))<FA8R?V@!0!R4HS;2RK2V:
M %LUW=L3\*+)W  4!DB1JP]M>.%EC[A"D3]BA8_Q3L(5"?$?["H3X7QS_F;V
M5$L= TBJ1[86CR./Z?\ MTJ/P!CV%#\#[? ZC#-TUZHZM-LF*TREHVU:;L>?
MV#8*^&W+,7L+;US(;/L%W8\LT-K':KL.)S&#7)7[5G':Y+K>.NQ2RL]O;+-I
MWO>H'4]MU4CN4C0JVZKD45^XC]P((+4:*D^]@@GI)A+;;" &! )8G80;&"I!
M6J 2C7&X5N+B=*^G62T+6+&&R-RID+V4V/;MMRTE"H*..&6VS8+NP6J^-J/:
MLRUZ%>Q>EBIQ36)I8:Z1Q//(8P[N-%HM3$BK., W1965:"* H#84*&JE%< #
MHZAPM.VXFRP6P <4%)HUBZP,_:SE[MI&2V/8^F65K2E:VF;KD-AR$;RIS:IV
MNG>\:K'$0TB_,HN;2O\ :93P#))V!.]_3G4Z65RIBL$'(#@6 &K)(Q9JK]Q>
M+/7$,2,D -[?Y?2?FR,$42 /BNG)^V9JT2/&K2B)5<OV,2_QA69W/)+!B6)_
M/N(YY)((=B,MIDCD 9A$BL']7J"4<FPV<$DB[.:)/0U[U7XK[<_<'/N,7S74
M7\1T]ZQ:I?V^'$8/IEF<5LF][3ME:YD=@S>/R45/.9N[DZ=3(5H-4MPRRU()
MXHC&EFQ#$R%(I&0*QK^H[5.9':&"+UN6W QH3;.5O*F@""11R019&$RA#-2H
M0[;FL Y'N38)))OAJ-D59N3V*6^N)QJ95*L>57'4UR4=&62>E'D!6C%Q*<TT
M4$TM5;/R+7EE@ADDB".\4;$H+!"C+IH8W \Q8(T86"-ZQA6HY'[KSD=+9]\G
MW(X)]^<_WZ:C<\5U2GS<\NKX[1=BP,^/>J<)N#W=>2">Q#\-FTFR8R#<+%])
M49HY<1+IN+CEA'Q/FW5B#$:OM\\KEHT1AD^KRP+-V";!R#[ 7><YZ->39)P.
M0-H-#X]1/R;Y JATMTBZ=Y+IUI<6NW+5,SRY/8,U)2PHDAPF"?.967)C7=:6
M;X9JVN8KYOL</6^"L*]"O!$8(2H4/M-#J(HHHV+#9$J;0X(4J%6E-_LH&A5
M7C.T :O%_<G-T>3=DV.?MCD67A4<*!^N !P/'' _0X_7'Z''I^.!?QT'7WT/
,7=5Z[KNJ]=UW7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
